• Explore /
  • Poster
  • / Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.

Phase I dose-escalation study of AZD7762 alone and in combination with gemcitabine in Japanese patients with advanced solid tumors.

Abstract Poster

Authors

null

Takashi Seto

National Kyushu Cancer Center, Fukuoka, Japan

Takashi Seto , Taito Esaki , Fumihiko Hirai , Shuji Arita , Kaname Nosaki , Akitaka Makiyama , Takuro Kometani , Chinatsu Fujimoto , Motoharu Hamatake , Hiroaki Takeoka , Felix Agbo , Xiaojin Shi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics - Experimental Therapeutics

Track

Developmental Therapeutics

Sub Track

Cell Cycle and Checkpoints

Clinical Trial Registration Number

NCT00937664

Citation

J Clin Oncol 30, 2012 (suppl; abstr 3045)

DOI

10.1200/jco.2012.30.15_suppl.3045

Abstract #

3045

Poster Bd #

13C

Abstract Disclosures

Similar Posters

First Author: David Sommerhalder

First Author: Patricia LoRusso

Poster

2020 ASCO Virtual Scientific Program

Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.

Phase I study of the combination of alisertib (MLN8237) and gemcitabine in advanced solid tumors.

First Author: Jasmine Huynh

First Author: Niven R. Narain